Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00750139 · ClinicalTrials.gov registry record · Phase 3
Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis
A Phase 3 study, sponsored by Merz North America.
- Completed
- Registry status
- Phase 3
- Development phase
- 707
- Enrollment target
NCT00750139: Completed Phase 3 study, sponsored by Merz North America.
NCT00750139 is a Phase 3 study that has completed, run by Merz North America. The registered enrollment target is 707 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00750139, a Phase 3 study, has completed, sponsored by Merz North America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 707 participants
- Enrollment target
Study Summary
A research study to compare the safety and effectiveness of an investigational medication called NAFT-500 to placebo, when used in subjects with tinea pedis (athlete's foot).
Primary Outcome
The first primary efficacy variable was the percentage of subjects in the NAFT-500 Cream, 2% or 2-week placebo groups with complete cure at Week 6. The second primary efficacy variable was the percentage of subjects in the Naftin 1% Cream or 4-week placebo groups with complete cure at Week 6. Complete cure was defined as negative mycology results from the central laboratory (dermatophyte culture and KOH) and absence of erythema, scaling, and pruritus that were evaluated using a 4 point severit
Interventions
- DRUG NAFT-500
- DRUG Placebo 2-weeks
- DRUG Naftin 1%
- DRUG Placebo 4-weeks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 707 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-12 |
| Phase | Phase 3 |
What the finished NCT00750139 record still lists
NCT00750139 is an interventional study that assigns participants to a tested intervention. The registered 707 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 4 interventions - of which NAFT-500 is the first listed.
NCT00750139 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00750139 about?
NCT00750139 is a clinical study titled "Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis". A research study to compare the safety and effectiveness of an investigational medication called NAFT-500 to placebo, when used in subjects with tinea pedis (athlete's foot).
What is the current status of trial NCT00750139?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 707 participants. The study started on 2008-08. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00750139?
The interventions under investigation include: NAFT-500 (DRUG), Placebo 2-weeks (DRUG), Naftin 1% (DRUG), Placebo 4-weeks (DRUG).
Who is sponsoring clinical trial NCT00750139?
This trial is sponsored by Merz North America, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00750139's enrollment target sits among peer trials
707 505th of 2000 higher than 1,496 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06480383 · 705 participants · Phase 2
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
- NCT07067463 · 705 participants · Phase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- NCT06235697 · 710 participants · Phase 3
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia